

AD \_\_\_\_\_

GRANT NO: DAMD17-94-J-4122


TITLE: Structure and Function of the Ankyrin Repeats in the SWI4/SWI6  
Transcription Complex of Budding Yeast

PRINCIPAL INVESTIGATOR: Linda Breeden, Ph.D.

CONTRACTING ORGANIZATION: Fred Hutchinson Cancer Research Center  
1124 Columbia Street  
Seattle, WA 98104

REPORT DATE: 8 August 1995

TYPE OF REPORT: Annual



PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;  
distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

19950901 042

DTIC QUALITY INSPECTED 8



REPORT DOCUMENTATION PAGE			Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.				
1. AGENCY USE ONLY (Leave blank)	2. REPORT DATE 8 August 95	3. REPORT TYPE AND DATES COVERED Annual 8 Jul 94 - 7 Jul 95		
4. TITLE AND SUBTITLE Structure and Function of the Ankyrin Repeats in the SWI4/SWI6 Transcription Complex of Budding Yeast		5. FUNDING NUMBERS DAMD17-94-J-4122		
6. AUTHOR(S) Linda Breeden, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Fred Hutchinson Cancer Research Center Seattle, Washington 98104		8. PERFORMING ORGANIZATION REPORT NUMBER		
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012		10. SPONSORING/MONITORING AGENCY REPORT NUMBER		
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION/AVAILABILITY STATEMENT Approved for public release, distribution unlimited		12b. DISTRIBUTION CODE		
13. ABSTRACT (Maximum 200 words) <p>The intent of this research is to define the structure and function of a highly conserved protein motif whose ectopic expression causes leukaemia, lymphoma, and mammary carcinoma. This protein motif, called an ankyrin or ANK repeat has been found in a diverse set of proteins in bacteria, plants, fungi, insects, and vertebrates. The ANK repeat is 33 amino acids long and is always tandemly repeated. The analysis that has been carried out indicates that the ANK repeats are required for the activity of the proteins in which they reside, but little progress has been made in defining their function. Deletions within the ANK repeat domains of several proteins suggest that the repeat may be involved in protein:protein interaction.</p> <p>We are identifying the critical residues and the biological function of the ANK repeats found in two yeast transcription factors. Using yeast allows us to simultaneously exploit genetic screens, gene replacement, biochemistry and immunochemistry in this analysis. A thorough investigation of these repeats in a simple system will provide insight and testable predictions which will augment and expedite their analysis in higher cell ANK proteins. It will also provide valuable reagents for identifying other ANK repeat proteins and defining their functions.</p>				
14. SUBJECT TERMS ankyrin repeat, yeast, SWI6, int-3, bcl-3, genetics		15. NUMBER OF PAGES 13		
		16. PRICE CODE		
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	



## GENERAL INSTRUCTIONS FOR COMPLETING SF 298

The Report Documentation Page (RDP) is used in announcing and cataloging reports. It is important that this information be consistent with the rest of the report, particularly the cover and title page. Instructions for filling in each block of the form follow. It is important to **stay within the lines** to meet optical scanning requirements.

**Block 1. Agency Use Only (Leave blank).**

**Block 2. Report Date.** Full publication date including day, month, and year, if available (e.g. 1 Jan 88). Must cite at least the year.

**Block 3. Type of Report and Dates Covered.** State whether report is interim, final, etc. If applicable, enter inclusive report dates (e.g. 10 Jun 87 - 30 Jun 88).

**Block 4. Title and Subtitle.** A title is taken from the part of the report that provides the most meaningful and complete information. When a report is prepared in more than one volume, repeat the primary title, add volume number, and include subtitle for the specific volume. On classified documents enter the title classification in parentheses.

**Block 5. Funding Numbers.** To include contract and grant numbers; may include program element number(s), project number(s), task number(s), and work unit number(s). Use the following labels:

<b>C</b> - Contract	<b>PR</b> - Project
<b>G</b> - Grant	<b>TA</b> - Task
<b>PE</b> - Program Element	<b>WU</b> - Work Unit Accession No.

**Block 6. Author(s).** Name(s) of person(s) responsible for writing the report, performing the research, or credited with the content of the report. If editor or compiler, this should follow the name(s).

**Block 7. Performing Organization Name(s) and Address(es).** Self-explanatory.

**Block 8. Performing Organization Report Number.** Enter the unique alphanumeric report number(s) assigned by the organization performing the report.

**Block 9. Sponsoring/Monitoring Agency Name(s) and Address(es).** Self-explanatory.

**Block 10. Sponsoring/Monitoring Agency Report Number.** (If known)

**Block 11. Supplementary Notes.** Enter information not included elsewhere such as: Prepared in cooperation with...; Trans. of...; To be published in.... When a report is revised, include a statement whether the new report supersedes or supplements the older report.

**Block 12a. Distribution/Availability Statement.** Denotes public availability or limitations. Cite any availability to the public. Enter additional limitations or special markings in all capitals (e.g. NOFORN, REL, ITAR).

**DOD** - See DoDD 5230.24, "Distribution Statements on Technical Documents."

**DOE** - See authorities.

**NASA** - See Handbook NHB 2200.2.

**NTIS** - Leave blank.

**Block 12b. Distribution Code.**

**DOD** - Leave blank.

**DOE** - Enter DOE distribution categories from the Standard Distribution for Unclassified Scientific and Technical Reports.

**NASA** - Leave blank.

**NTIS** - Leave blank.

**Block 13. Abstract.** Include a brief (*Maximum 200 words*) factual summary of the most significant information contained in the report.

**Block 14. Subject Terms.** Keywords or phrases identifying major subjects in the report.

**Block 15. Number of Pages.** Enter the total number of pages.

**Block 16. Price Code.** Enter appropriate price code (*NTIS only*).

**Blocks 17. - 19. Security Classifications.** Self-explanatory. Enter U.S. Security Classification in accordance with U.S. Security Regulations (i.e., UNCLASSIFIED). If form contains classified information, stamp classification on the top and bottom of the page.

**Block 20. Limitation of Abstract.** This block must be completed to assign a limitation to the abstract. Enter either UL (unlimited) or SAR (same as report). An entry in this block is necessary if the abstract is to be limited. If blank, the abstract is assumed to be unlimited.



## FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the US Army.

Where copyrighted material is quoted, permission has been obtained to use such material.

Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

*SB* In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

*SB* In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

*SB* In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

Accession For	
NTIS GRA&I	<input checked="" type="checkbox"/>
DTIC TAB	<input type="checkbox"/>
Unannounced	<input type="checkbox"/>
Justification	
By	
Distribution/	
Availability Codes	
Dist	Avail and/or Special
A-1	

*Linda Breeden*  
PI - Signature Date



## TABLE OF CONTENTS

INTRODUCTION	2
RESULTS	3
CONCLUSIONS	8
REFERENCES	9



## INTRODUCTION

Ankyrin (or ANK) repeats were first identified in Swi6, a budding yeast protein involved in cell cycle regulated transcription, and in fission yeast homolog of Swi6 (Cdc10) (5). The repeats are called ankyrin repeats because ankyrin, a cytoskeletal protein, contains 22 tandem repeats of this 33 amino acid sequence (18). ANK repeats have also been found in other transcription factors, trans-membrane signalling molecules, toxins, viral host range proteins, and other proteins of unknown function (2). Most recently small ANK repeat proteins have been identified that bind to and inhibit cyclin-dependent kinases (7,11) and the ectopic expression of ANK domains have been shown to leukemia and breast cancer (10,17,20,21).

The number and position of ANK repeats within a protein varies, but they are always found in multiple copies. It is possible that ANK-containing proteins are related to each other, in fact it seems likely that they are all related in some fundamental way, however that is pure speculation at this point. A thorough investigation of the role of the ANK repeats in any one of these proteins will allow us to make educated guesses about the role of the repeats found in other proteins. This would be particularly useful for understanding and overcoming the malignant transformation caused by ANK repeat proteins in murine and human cells.

The consensus sequence of the ANK repeat for the Swi6 family of proteins is shown in Fig. 1, however the consensus within a given repeat, will also vary. Aside from a few relatively invariant residues, there is considerable sequence heterogeneity within the repeats. In addition to the actual sequence conservation, there is some further conservation of hydrophobic and charged residues within the repeats. These could form short amphipathic alpha helices (18), and circular dichroism studies of the ANK domain of ankyrin confirm that it is 30% alpha helical (9).

Despite their persistent occurrence in tandemly repeated arrangements, single mutations in one repeat can result in dramatic loss of activity. The glp-1 protein contains six ANK repeats, however, six different single amino acid substitutions within the ANK repeat domain of glp-1 have been found that cause a temperature sensitive loss of function phenotype (16). A lysine substitution for the most conserved leucine in one ANK repeat of Swi6 also dramatically reduces Swi6 function (1).

There is some evidence for divergence of function in the repeats of ankyrin. Ankyrin is a cytoskeletal protein that binds several proteins, including anion exchange protein and tubulin. The ANK repeat domain is required for binding to both proteins, and there is some evidence that specific repeats within ankyrin are more critical for binding to anion exchange protein than others (9,18). Deletion analysis of several ANK repeat-containing proteins has suggested that the repeats are required for association with other proteins which do not themselves contain repeats (15,25). However, these experiments have all involved large deletions which may cause significant conformational changes outside the repeat domain. Direct contact has not been demonstrated between ankyrin repeats and other proteins, nor have any homologies been observed among the diverse group of proteins to which ANK proteins are known to bind. It is possible that the repeats play an indirect role, by allowing the protein to



adopt a conformation that promotes binding to other proteins, or they may bind through a common intermediate that has not yet been identified.

The experiments that we are carrying out are designed to determine how many functional repeats exist in Swi4 and Swi6, and to identify the critical residues in the repeats of both proteins. We are also defining the biological function of the ANK repeats of both Swi4 and Swi6 through a series of genetic, immunochemical and biochemical assays. Swi4 and Swi6 are members of an evolutionarily conserved family of transcription factors. In budding yeast, they control the expression of the G1 cyclins, which are the rate limiting components of the kinase complex which controls the G1 to S transition. Swi6 complexes with another member of this family of transcription factors, Mbp1, to activate transcription of most of the genes whose products are involved in DNA synthesis. Swi4/6 and Mbp1/Swi6 mediated transcription occurs primarily during the late G1/early S phase of the cell cycle via promoter elements called SCBs and MCBs. The ANK repeats of Swi4 and Swi6 are required for the activities of both proteins, but their actual function is not known.

## RESULTS

The purpose of this investigation is to define the function of the ANK repeats in Swi4 and Swi6. We are exhaustively mutagenizing the ANK repeats of Swi4 and Swi6 to identify the critical residues within each repeat. We have planned a series of genetic screens and biochemical assays to screen these mutants and identify the *in vivo* and *in vitro* functions that they effect. Partially defective mutants, and mutants that have lost specific functions will be used to identify interacting gene products using suppressor analysis. We are also generating monoclonal antibodies that recognize either Swi4, Swi6 or all ANK repeats. The precise binding specificity of these antibodies will be identified, and their ability to interfere with specific biochemical functions will be tested. Antibodies that recognize general features of the ANK repeats will be used to identify other ANK proteins of yeast and humans.

Our specific Technical Objectives are to:

1. Generate monoclonal and polyclonal antibodies that recognize either Swi4, Swi6 or all ANK repeats and use them to screen for other ANK repeat-containing proteins.
2. Exhaustively mutagenize the ANK repeats of Swi4 and Swi6, and identify the crucial residues for their activity.
3. Develop a battery of genetic screens to identify mutations that cause loss or deregulation of known Swi4 and Swi6 functions.
4. Perform *in vitro* assays to correlate mutant phenotypes with known biochemical functions.



5. Identify second site suppressors, either within the Swi6 protein, or within associated proteins.

We have made significant progress on objectives one, two and five. Our results are summarized below.

**Task 1. Generating monoclonal antibodies that recognize Swi6 and the ANK repeat region of Swi6.**

We have generated monoclonal antibodies to full length Swi6 and the ANK domain of Swi6, as described in my research proposal. Table 1 summarizes the monoclonal cell lines that have been generated and the extent to which they've been characterized.

Table 1. Monoclonal antibodies generated in this study.

Antibodies positive for use in:				
Fusion Number	Immunogen	ELISA	Western Blot	Immunoprecipitation
1	Swi6 repeat domain	24	11	1
2	Swi6 repeat domain	57	14	0
3	Swi6	33	0	0
4	Swi6	35	4	2

Monoclonal production using RBF/DnJ mice was carried out as described (24). ELISA, Western Blot and immunoprecipitation techniques were carried out using standard protocols (14).

We are in the early stages of characterizing these antibodies, and using them for analyzing Swi6 and ANK repeat function. The results of these studies will be described in later progress reports. So far none of the antibodies that we have generated react with other *S. cerevisiae* proteins besides Swi6. Our efforts to screen these antibodies for cross reactivity with the Cdc10 protein of *S. pombe* have been inconclusive.

**Task 2. Defining critical residues within the ANK repeat domain of Swi6.**

The first step in the analysis of the ANK repeat domain of Swi4 and Swi6 was an alignment and comparison of the ANK repeat domains of the eight known members of this family of transcription factors. Fig. 1 shows this alignment which I have submitted for publication (3) in a review on this subject.






Figure 1. Alignment of the Swi6/Cdc10 repeat domain shows the residues common to all five repeats in black and the residues conserved in a subset of the repeats in grey. In addition, boxed residues indicate amino acids that are conserved in at least four family members but only within a single repeat. The consensus sequence for individual repeats is shown below the alignment. Capital letters denote identity in all eight family members, lower case residues are conserved in at least half of the sequences, and a lower case o denotes positions that are always hydrophobic. The high propensity for proline residues preceding the Swi6/Cdc10 repeat domain is emphasized by underlines. Also underlined in the consensus sequence of repeats I and IV, are the positions of the six alanine substitutions in Swi6 that inactivate Swi6 and disrupt DNA binding. This alignment represents the contiguous sequences of all eight family members except for small nonhomologous inserts that exist in three of the proteins after repeat III. The length of the omitted sequence is noted.



It is apparent from this alignment (Fig. 1) that there is considerable homology throughout the ANK region (black and grey shaded residues). This conservation suggests the existence of 4.5 repeats. There is further homology (boxed residues) within a given repeat, which makes the consensus sequence for each repeat slightly different. The homologies evident from this alignment make it possible for us to interpret the mutations that we have generated in Swi6.

Mutagenic PCR (6) was used to produce three different library's of ANK domain plasmid-borne mutants of Swi6. These were made with different PCR conditions to produce different frequencies of mutations. We have screened for all types of defects in Swi6, but have focussed most of our attention on temperature sensitive mutants that are very defective in *HO:lacZ* transcription at 37° and active at 25°. These plasmid-borne mutants were tested to make sure the ts mutation was carried by the plasmid and that the Swi6 protein was still accumulating at the high temperature. The latter test insured that the mutations are affecting function rather than just the stability of the protein at high temperature, then these mutants were sequenced. A summary of this work is provided as Table 2.

Table 2. Mutagenesis of the ANK domain of Swi6.

Library	Bd1681	BD1824	BD1825
MnCl <sub>2</sub>	.5 mM	.25 mM	.1 mM
Complexity	300	1,000	1,000
Total Mutants Isolated	85	7	18
Temperature Sensitive	18 (8)	5 (5)	7 (7)
Null	52	2	7
Partial Activity	15	0	4

Each library was fully screened (>4 x complexity). The numbers in parentheses represent the number of these mutants that have been sequenced.

Most of the mutants we have characterized so far contain more than one mutation and many of these reside in residues whose importance to function was unknown. Thus, from this analysis we have more evidence of the importance of unique residues in individual repeats than we have of the importance of consensus residues.

To test directly whether the consensus residues in each of the four complete ANK repeats are critical for function of Swi6, we made four site-directed mutants in which the conserved core of each repeat: G-T-L, was changed to A-A-A. We then measured *HO:lacZ* expression by filter (4) and liquid (19) assays and the liquid assay results are shown in Table 2. The consensus residues in the fourth repeat are clearly the most critical



for function, but mutations in each of the four conserved cores cause a loss of function when mutated to alanines. The fact that the conserved residues that were changed are important for Swi6 activity suggests that this region contains four functional repeats. The importance of the fifth half repeat has not yet been investigated.

Table 3. All four ANK repeats of Swi6 contribute to *HO:lacZ* activation.

PLASMID	SWI6 ALLELE	<i>HO:lacZ</i> activity
BD1378	Swi6 WT	12.64
BD1819	Swi6 3A-1	1.99
BD1820	Swi6 3A-2	0.57
BD1821	Swi6 3A-3	0.38
BD1822	Swi6 3A-4	0.05
None	--	0.00

Wild type and Swi6 mutants bearing three alanine substitutions in ANK repeat 1 (3A-1) through 4 (3A-4) were expressed on plasmids in a  $\Delta swi6$  *HO:lacZ* strain (BY600). These strains were assayed for *HO:lacZ* expression as described (4,19).

These triple mutants were screened only for loss of function using the *HO:lacZ* reporter, so other Swi6-dependent activities will have to be assayed. These include activation of MCB regulated promoters, alfa factor recovery, and a new phenotype, which is hypersensitivity to mutagens. Once the spectrum of Swi6-dependent activities are tested, we will know if mutations in each of the repeats has an equivalent impact on all Swi6 functions, or if they differ. If each repeat has a different primary function this should be evident from this analysis. If individual repeats show a differential importance in any of these assays, this information will be useful for screening for other mutations in the critical residues in each repeat.

#### Task 5. Suppressors of temperature sensitive ANK mutants.

Suppression of leaky or temperature sensitive mutations has been widely used to identify other proteins that interact with the mutant protein. The rationale is that slight defects or instabilities within an interaction domain can be suppressed either by compensating mutations, or by overproduction of the binding partner. Both G1 and G2 cyclins have been identified in this way (13,23), as well as many other interacting yeast proteins (8,12).

We have generated three libraries of Swi6 ankyrin repeat mutants, with complexities of about 2000 mutants each, using mutagenic PCR (see Task 2). We have screened these libraries and selected 17 mutants of Swi6 that are ts for *HO::LacZ* transcription and that continue to accumulate Swi6 protein at the high temperature. This was a necessary second criteria because if the protein was degraded, overproduction of its binding partner could not suppress its defect. We've integrated eight of these mutants into the yeast genome for further study and activity measurements (22). We have also screened for high copy suppressors of the ts phenotype for two of them: swi6-B38 and



swi6-B19. Two more, swi6-wh6 (a double) and swi6-4-10 (a single) show high degree of reversion and are unsuitable for suppressor screens.

We have isolated two high copy suppressors in this analysis, one of which bypasses a *swi6* null mutant and therefore must be activating Swi6 target promoters in a Swi6-independent manner. This suppressor is not relevant to the analysis of Swi6 function, but may be useful in other studies. The second high copy suppressor is allele specific. It suppresses ANK mutant B19, but it does not suppress *swi6* deletions or other mutations elsewhere in the protein. This overexpressed gene is a good candidate for encoding a protein that interacts with the ANK domain of Swi6. We are currently sequencing this gene, and fully characterizing its allele specific suppression.

## CONCLUSIONS

**Some portion of the ANK domain of Swi6 is accessible to antibodies in the native state.** Swi6 is an antigenic protein, as are the ANK repeats in isolation. The fact that at least one monoclonal antibody generated against the ANK domain can be used to immunoprecipitate Swi6 from yeast extracts suggests that some portion of the ANK domain is accessible in the native state. Not all of the antibodies have been assayed for immunoprecipitation as yet. This work is underway. We had hoped that the ANK repeat fragment of Swi6 would be soluble and properly folded as produced in *E. coli*, but this is not the case. This means that this protein preparation is not ideal for generating antibodies to native structure. Thus we have shifted to using full length Swi6, which we know is functional as the immunogen.

**There are at least four functional ANK repeats in Swi6.** The fourth repeat of Swi6 is the most critical for Swi6 function, but the conserved core of each repeat is important for Swi6-mediated activation of HO:*lacZ* transcription. It will be important to determine at what level the defect manifests itself. It will also be interesting to see if individual repeats have different impacts on other Swi6-dependent processes (MCB activation,  $\alpha$  factor recovery, etc.).

**Many residues within the ANK domain are critical for function.** ANK domain mutations have been identified that cause Swi6 to be temperature sensitive for function. Mutants across the spectrum of severity have been isolated from this screen. We have focussed upon temperature sensitive ones, but many non-conditional null mutants have also been isolated. These will be characterized in the future. Judging from the analysis so far it is clear that the ANK domain of Swi6 contains a large number of residues that are critical for its function.

**A candidate ANK domain interacting protein has been identified by high copy suppression.** Allele-specific suppression has been used to identify many interacting proteins. The suppressor we have identified selectively suppresses mutations within the ANK domain of Swi6. Our intent is to identify this gene and test the prediction that it binds to the ANK domain of Swi6 using immunoprecipitation. Our monoclonal antibodies and the starting mutants will be valuable tools for this analysis.



## REFERENCES

1. Andrews, B. J. and L. A. Moore. 1992. Interaction of the yeast Swi4 and Swi6 cell cycle regulatory proteins *in vitro*. Proc. Natl. Acad. Sci. USA 89:11852-11856.
2. Bork, P. 1993. Hundreds of ankyrin-like repeats in functionally diverse proteins: mobile modules that cross phyla horizontally. Proteins: Structure, Function, and Genetics 17:363-374.
3. Breeden, L. 1995. Start-specific transcription factors in yeast. Anonymous Current Topics in Microbiology and Immunology.
4. Breeden, L. and K. Nasmyth. 1985. Regulation of the yeast *HO* gene. Cold Spring Harbor Symp. Quant. Biol. 50:643-650.
5. Breeden, L. and K. Nasmyth. 1987. Similarity between cell-cycle genes of budding yeast and fission yeast and the *Notch* gene of *Drosophila*. Nature 329:651-654.
6. Cadwell, R. C. and G. F. Joyce. 1992. Randomization of genes by PCR mutagenesis. PCR Methods and Applications 2:28-33.
7. Cairns, P., L. Mao, A. Merlo, D. J. Lee, D. Schwab, Y. Eby, K. Tokino, P. van der Riet, J. E. Blaugrund, and D. Sidransky. 1994. Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science 265:415-416 (response-417).
8. Colbert, T. and S. Hahn. 1992. A yeast TFIIB-related factor involved in RNA polymerase III transcription. Genes & Dev. 6:1940-1949.
9. Davis, L. H., E. Otto, and V. Bennett. 1991. Specific 33-residue repeat(s) of erythrocyte ankyrin associate with the anion exchanger. J. Biol. Chem. 266:11163-11169.
10. Ellisen, L. W., J. Bird, D. C. West, A. L. Soreng, T. C. Reynolds, S. D. Smith, and J. Sklar. 1991. *TAN-1*, the human homolog of the *Drosophila Notch* gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 66:649-661.
11. Guan, K. L., C. W. Jenkins, Y. Li, M. A. Nichols, X. Wu, C. L. O'Keefe, A. G. Matera, and Y. Xiong. 1994. Growth suppression by p18, a p16<sup>INK4/MTS1</sup>- and p14<sup>INK4B/MTS2</sup>- related CDK6 inhibitor, correlates with wild-type pRb function. Genes Devel 8:2939-2952.
12. Hadwiger, J. A., C. Wittenberg, M. D. Mendenhall, and S. I. Reed. 1989. The *Saccharomyces cerevisiae CKS1* gene, a homolog of the *Schizosaccharomyces pombe suc1+* gene, encodes a subunit of the CDC28 protein kinase complex. Mol. Cell. Biol. 9:2034-2041.



13. Hadwiger, J. A., C. Wittenberg, H. E. Richardson, M. De Barros Lopes, and S. I. Reed. 1989. A family of cyclin homologs that control the G1 phase in yeast. *Proc. Natl. Acad. Sci. USA* 86:6255-6259.
14. Harlow, E. and D. Lane. 1988. *Antibodies - A Laboratory Manual*. Cold Spring Harbor Laboratory, Cold Spring Harbor.
15. Henkel, T., U. Zabel, K. van Zee, J. M. Muller, E. Fanning, and P. A. Baeuerle. 1992. Intramolecular masking of the nuclear location signal and dimerization domain in the precursor for the p50 NF kappa B subunit. *Cell* 68:1121-1133.
16. Kodoyianni, V., E. M. Maine, and J. Kimble. 1992. Molecular basis of loss-of-function mutations in the *glp-1* gene of *Caenorhabditis elegans*. *Mol. Biol. of the Cell* 3:1199-1213.
17. Lu, D., J. D. thompson, G. K. Gorski, N. R. Rice, M. G. Mayer, and J. J. Yunis. 1991. Alterations at the *c-rel* locus in human lymphoma. *Oncogene* 6:1235-1241.
18. Lux, S. E., K. M. John, and V. Bennett. 1990. Analysis of cDNA for human erythrocyte ankyrin indicates a repeated structure with homology to tissue-differentiation and cell-cycle control proteins. *Nature* 344:36-42.
19. Miller, J. H. 1972. Experiments in molecular genetics, p. 352-355. In Anonymous
20. Ohno, H., G. Takimoto, and T. W. McKeithan. 1990. The candidate proto-oncogene *bcl-3* is related to genes implicated in cell lineage determination and cell cycle control. *Cell* 60:991-997.
21. Robbins, J., B. J. Blondel, D. Gallahan, and R. Callahan. 1992. Mouse mammary tumor gene *int-3*: a member of the *Notch* gene family transforms mammary epithelial cells. *J. Virol.* 66:2594-2599.
22. Rothstein, R. 1983. One step gene disruption in yeast. *Meth. Enzymol.* 101:202-211.
23. Surana, U., H. Robitsch, C. Price, T. Schuster, I. Fitch, A. B. Futcher, and K. Nasmyth. 1991. The role of CDC28 and cyclins during mitosis in the budding yeast *S. cerevisiae*. *Cell* 65:145-161.
24. Taggart, R. T. and I. M. Samloff. 1983. Stable antibody-producing murine hybridomas. *Science* 219:1228-1230.
25. Thompson, C. C., T. A. Brown, and S. L. McKnight. 1991. Convergence of Ets- and Notch-related structural motifs in a heteromeric DNA binding complex. *Science* 253:762-768.